Amgen To Re-Submit Prolia BLA In "The Very Near Future"
This article was originally published in The Pink Sheet Daily
Executive Summary
At the J.P. Morgan Healthcare Conference, Amgen CEO Kevin Sharer said the development of REMS and post-approval safety surveillance has been holding the company up.